Matt Miksic
Stock Analyst at Barclays
(3.84)
# 467
Out of 4,804 analysts
270
Total ratings
56.88%
Success rate
3.12%
Average return
Main Sectors:
Stocks Rated by Matt Miksic
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BAX Baxter International | Maintains: Overweight | $39 → $41 | $30.75 | +33.33% | 21 | Mar 10, 2025 | |
| LIVN LivaNova | Maintains: Equal-Weight | $58 → $56 | $35.72 | +56.77% | 6 | Mar 7, 2025 | |
| TNDM Tandem Diabetes Care | Maintains: Overweight | $60 → $53 | $17.61 | +200.97% | 6 | Feb 28, 2025 | |
| GMED Globus Medical | Maintains: Overweight | $100 → $103 | $74.28 | +38.66% | 14 | Feb 24, 2025 | |
| EW Edwards Lifesciences | Maintains: Overweight | $88 → $90 | $69.90 | +28.76% | 28 | Feb 13, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Underweight | $118 → $112 | $103.44 | +8.28% | 7 | Feb 10, 2025 | |
| SYK Stryker | Maintains: Overweight | $418 → $443 | $362.97 | +22.05% | 23 | Feb 10, 2025 | |
| BSX Boston Scientific | Maintains: Overweight | $111 → $118 | $96.77 | +21.94% | 16 | Feb 10, 2025 | |
| INMD InMode | Maintains: Overweight | $26 → $29 | $15.46 | +87.58% | 12 | Feb 5, 2025 | |
| JNJ Johnson & Johnson | Maintains: Equal-Weight | $159 → $166 | $150.97 | +9.96% | 11 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $149 → $158 | $127.04 | +24.37% | 28 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $21 | $10.05 | +108.96% | 2 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $3.20 | +587.50% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $16 | $2.93 | +446.08% | 1 | Jan 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $109 | $85.28 | +27.81% | 21 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $220 → $234 | $264.72 | -11.60% | 7 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $138 → $113 | $66.84 | +69.06% | 5 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $490 → $510 | $522.95 | -2.48% | 6 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $13 → $16 | $9.60 | +66.67% | 7 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $17 → $18 | $12.53 | +43.66% | 4 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $96 | $89.99 | +6.68% | 9 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $100 | $66.16 | +51.15% | 8 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $722 → $418 | $165.03 | +153.29% | 3 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $28 | $11.32 | +147.35% | 2 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $67 | $13.66 | +390.48% | 1 | Mar 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $480 | $5.71 | +8,306.30% | 1 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $84 → $87 | $19.19 | +353.36% | 14 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $4.08 | +512.75% | 5 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $9 | $7.16 | +25.70% | 1 | Dec 12, 2016 |
Baxter International
Mar 10, 2025
Maintains: Overweight
Price Target: $39 → $41
Current: $30.75
Upside: +33.33%
LivaNova
Mar 7, 2025
Maintains: Equal-Weight
Price Target: $58 → $56
Current: $35.72
Upside: +56.77%
Tandem Diabetes Care
Feb 28, 2025
Maintains: Overweight
Price Target: $60 → $53
Current: $17.61
Upside: +200.97%
Globus Medical
Feb 24, 2025
Maintains: Overweight
Price Target: $100 → $103
Current: $74.28
Upside: +38.66%
Edwards Lifesciences
Feb 13, 2025
Maintains: Overweight
Price Target: $88 → $90
Current: $69.90
Upside: +28.76%
Zimmer Biomet Holdings
Feb 10, 2025
Maintains: Underweight
Price Target: $118 → $112
Current: $103.44
Upside: +8.28%
Stryker
Feb 10, 2025
Maintains: Overweight
Price Target: $418 → $443
Current: $362.97
Upside: +22.05%
Boston Scientific
Feb 10, 2025
Maintains: Overweight
Price Target: $111 → $118
Current: $96.77
Upside: +21.94%
InMode
Feb 5, 2025
Maintains: Overweight
Price Target: $26 → $29
Current: $15.46
Upside: +87.58%
Johnson & Johnson
Jan 28, 2025
Maintains: Equal-Weight
Price Target: $159 → $166
Current: $150.97
Upside: +9.96%
Jan 27, 2025
Maintains: Overweight
Price Target: $149 → $158
Current: $127.04
Upside: +24.37%
Jan 22, 2025
Maintains: Overweight
Price Target: $20 → $21
Current: $10.05
Upside: +108.96%
Jan 7, 2025
Initiates: Overweight
Price Target: $22
Current: $3.20
Upside: +587.50%
Jan 2, 2025
Initiates: Overweight
Price Target: $16
Current: $2.93
Upside: +446.08%
Nov 26, 2024
Maintains: Overweight
Price Target: $105 → $109
Current: $85.28
Upside: +27.81%
Nov 11, 2024
Maintains: Equal-Weight
Price Target: $220 → $234
Current: $264.72
Upside: -11.60%
Jul 29, 2024
Maintains: Equal-Weight
Price Target: $138 → $113
Current: $66.84
Upside: +69.06%
Jul 23, 2024
Maintains: Overweight
Price Target: $490 → $510
Current: $522.95
Upside: -2.48%
Mar 5, 2024
Maintains: Underweight
Price Target: $13 → $16
Current: $9.60
Upside: +66.67%
Feb 26, 2024
Maintains: Equal-Weight
Price Target: $17 → $18
Current: $12.53
Upside: +43.66%
May 13, 2022
Assumes: Outperform
Price Target: $96
Current: $89.99
Upside: +6.68%
May 13, 2022
Assumes: Outperform
Price Target: $100
Current: $66.16
Upside: +51.15%
May 4, 2022
Maintains: Outperform
Price Target: $722 → $418
Current: $165.03
Upside: +153.29%
Mar 2, 2022
Maintains: Outperform
Price Target: $31 → $28
Current: $11.32
Upside: +147.35%
Mar 1, 2022
Maintains: Outperform
Price Target: $68 → $67
Current: $13.66
Upside: +390.48%
Jan 7, 2022
Initiates: Outperform
Price Target: $480
Current: $5.71
Upside: +8,306.30%
Nov 3, 2021
Maintains: Outperform
Price Target: $84 → $87
Current: $19.19
Upside: +353.36%
Aug 10, 2021
Maintains: Outperform
Price Target: $24 → $25
Current: $4.08
Upside: +512.75%
Dec 12, 2016
Initiates: Sell
Price Target: $9
Current: $7.16
Upside: +25.70%